Replies to post #656 on PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[genisi]

On the Brazil label issue I think there's a draft version of the label not a final one. If we look at the clinical data, PLX' drug had lower antibody and similar hypersensitivity rates compared to Cerezyme, so there's no reason that I can see for a different label.